BioNTech Results Presentation Deck
BNT211: CAR-T Cell Program with Potential Targeting Multiple High-Need
Solid Tumors
2nd generation CAR-T
Directed against CLDN6
Cancer specific carcino-
●
●
●
embryonic antigen
Expressed in multiple solid.
cancers with high medical need
CARVac
drives in vivo expansion,
persistence and efficacy of CAR-T
BNT211 CAR Structure
22
extracellular
intracellular
aCLDN6 scFv
CD8 hinge
4-1BB
CD3
CLDN6 not present in healthy tissues
O
CLDN6 expressed in multiple cancers.
Patients with
CLDN6+ relapsed/
refractory solid
tumors
(up to 36 patients)
High
CLDN6
expression
CANCER IMMUNOTHERAPY
An RNA vaccine drives expansion and efficacy of
claudin-CAR-T cells against solid tumors
Katharina Reinhard¹*, Benjamin Rengstl¹*, Petra Oehm¹*, Kristina Michel¹, Arne Billmeier',
Nina Hayduk¹, Oliver Klein¹, Kathrin Kuna¹, Yasmina Ouchan¹, Stefan Wöll¹, Elmar Christ¹,
David Weber², Martin Suchan², Thomas Bukur², Matthias Birtel, Veronika Jahndel, Karolina Mroz¹,
Kathleen Hobohm², Lena Kranz', Mustafa Diken², Klaus Kühlcke¹, Özlem Türeci¹t, Ugur Sahin ¹,2,3++
Science
Part 1
CLDN6 CAR-T
dose escalation (3 dose levels)
Part 2
CLDN6 CAR-T dose
escalation + CLDN6 CARVac
CLDN6, Claudin-6; CAR-T cells, chimeric antigen receptor engineered T cells; scFv, single chain variable fragment; RP2D, recommended Phase 2 dose; NOS, not otherwise specified;
Reinhard K, et al. Science 2020; 367:446-453
RP2D
Part 3 Expansion
Cohorts
●
Ovarian Cancer
Testicular Cancer
Endometrial Cancer
Lung Cancer
Gastric Cancer
Tumors NOS
BIONTECHView entire presentation